A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
Inclusion Criteria:
Summerville, South Carolina 29486, United States
Ciudad Autónoma de Buenos Aire, Buenos Aires 1046, Argentina
Ciudad de Buenos Aires, Buenos Aires C1111AAH, Argentina
CABA, Ciudad Autónoma de Buenos Aire C1430EGF, Argentina
Buenos Aires, C1431FWO, Argentina
Salvador, Estado de Bahia 40150-150, Brazil
Nanjing, Jiangsu 210000, China
Hangzhou, Zhejiang 310009, China
Bogota, Cundinamarca, Colombia
Szeged, 6725, Hungary
Nashik, Maharashtra 422101, India
Kita-gun, Kagawa-ken 761-0793, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Bunkyo-Ku, Tokyo 113-8603, Japan
Shinagawa, Tokyo 142-8555, Japan
Guadalajara, Jalisco 44690, Mexico
San Luis Potosí City, San Luis Potosí 78213, Mexico
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Wroclaw, Lower Silesian Voivodeship 53224, Poland
Bialystok, Podlaskie Voivodeship 15-077, Poland
Bucureti, Bucharest 14461, Romania
Moscow, Russian Federation 117997, Russia
Novosibirsk, 630117, Russia
Rursk, 305007, Russia
Dalin Township, 622, Taiwan